## **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

51) International Patent Classification 5:		1) International Publication Number: WO 94/0011
A61K 31/135 A1	A1	3) International Publication Date: 6 January 1994 (06.01.9
22) International Application Number: PCT/US 22) International Filing Date: 22 June 1993 (30) Priority data: 903,040 23 June 1992 (23.06.92) 23 June 1992 (23.06.92) 24) Applicant: SEPRACOR INC. [US/US]; 33 Loc Marlborough, MA 01752 (US). 25) Inventor: YOUNG, James, W.; 295 Still River R River, MA 01467 (US). 26) Agents: LAWRENCE, Stanton, T., III et al.; Penn monds, 1155 Avenue of the Americas, New Y 10036 (US).	(22.06.9 kke Dri Road, S	(81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HI JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RI SD, SK, UA, European patent (AT, BE, CH, DE, DI ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MI NE, SN, TD, TG).  Published With international search report.

(54) Title: METHODS AND COMPOSITIONS FOR TREATING DEPRESSION AND OTHER DISORDERS USING OPTICALLY PURE (-) SIBUTRAMINE

## (57) Abstract

Methods and compositions are disclosed utilizing the optically pure (-) isomer of sibutramine, which is a potent drug for treatment of depression, Parkinson's disease, cerebral function disorders, obesity, dementia and related disorders, as well as other conditions related to the activity of the compound as an inhibitor of the neuronal reuptake of monoamines. Further, methods and compositions are disclosed utilizing optically pure (-) sibutramine in order to avoid the adverse effects associated with the administration of racemic sibutramine.